Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL).
Acute lymphoblastic leukemia
B cell
CAR-T
CD19
Chimeric antigen receptor
Journal
Cancer treatment and research
ISSN: 0927-3042
Titre abrégé: Cancer Treat Res
Pays: United States
ID NLM: 8008541
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
9
10
2021
pubmed:
10
10
2021
medline:
26
11
2021
Statut:
ppublish
Résumé
With the exploitation of adoptive immunotherapies, the outcomes of patients with relapsed and refractory B cell hematologic malignancies have seen drastic improvements. To this end, a paradigm shift away from toxic and ineffective chemotherapies has been visible with the FDA approval of genetically modified autologous T cell products designed to express chimeric antigen receptors able to specifically recognize the CD19 cell surface marker. To date, CAR-T cells have two FDA-approved indications including relapsed or refractory acute lymphoblastic leukemia in children and young adults as well as large B cell lymphoma that is relapsed and/or refractory to two prior therapies. This chapter will discuss the utility of this therapy in B-ALL, common toxicities and their management, relationship to other therapies such as stem cell transplantation, and future directions.
Identifiants
pubmed: 34626362
doi: 10.1007/978-3-030-78311-2_11
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-196Informations de copyright
© 2021. Springer Nature Switzerland AG.
Références
Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90(2):720–724
pubmed: 8421711
pmcid: 45737
doi: 10.1073/pnas.90.2.720
June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361–1365
pubmed: 29567707
doi: 10.1126/science.aar6711
pmcid: 29567707
Sadelain M (2015) CAR therapy: the CD19 paradigm. J Clin Invest 125(9):3392–3400
pubmed: 26325036
pmcid: 4588281
doi: 10.1172/JCI80010
Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N et al (2006) CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66(22):10995–11004
pubmed: 17108138
doi: 10.1158/0008-5472.CAN-06-0160
pmcid: 17108138
Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172(1):104–113
pubmed: 14688315
doi: 10.4049/jimmunol.172.1.104
pmcid: 14688315
Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK (2006) Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20(10):1819–1828
pubmed: 16932339
doi: 10.1038/sj.leu.2404366
pmcid: 16932339
Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 20(1):70–75
pubmed: 11753365
doi: 10.1038/nbt0102-70
pmcid: 11753365
Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G et al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121(5):1822–1826
pubmed: 21540550
pmcid: 3083795
doi: 10.1172/JCI46110
Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL et al (2010) 4–1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther 21(1):75–86
pubmed: 19719389
pmcid: 2861957
doi: 10.1089/hum.2009.122
Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG et al (2007) Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 18(8):712–725
pubmed: 17685852
doi: 10.1089/hum.2007.028
pmcid: 17685852
FDA Approval
Kenderian SS, Ruella M, Gill S, Kalos M (2014) Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res 74(22):6383–6389
pubmed: 25371415
doi: 10.1158/0008-5472.CAN-14-1530
pmcid: 25371415
Kochenderfer JN (2014) Genetic engineering of T cells in leukemia and lymphoma. Clin Adv Hematol Oncol 12(3):190–192
pubmed: 24927269
pmcid: 24927269
Maus MV, Grupp SA, Porter DL, June CH (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123(17):2625–2635
pubmed: 24578504
pmcid: 3999751
doi: 10.1182/blood-2013-11-492231
Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3(4):388–398
pubmed: 23550147
pmcid: 3667586
doi: 10.1158/2159-8290.CD-12-0548
Gill S, June CH (2015) Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 263(1):68–89
pubmed: 25510272
doi: 10.1111/imr.12243
pmcid: 25510272
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M et al (2016) CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 126(6):2123–2138
pubmed: 27111235
pmcid: 4887159
doi: 10.1172/JCI85309
Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D et al (2019) Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133(15):1652–1663
pubmed: 30728140
pmcid: 6460418
doi: 10.1182/blood-2018-11-883710
Turtle CJ, Hanafi LA, Berger C, Daniel Sommermeyer P, Barbara Pender MS, Emily M, Robinson BS, Melville K et al (2015) Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia. Blood 126(23):3773
Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF et al (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7(12):1404–1419
Park JH, Santomasso B, Riviere I, Senechal B, Wang X, Purdon T et al (2017) Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19–28z CAR T cells in adult patients with relapsed B-ALL. J Clin Oncol 35:7024
doi: 10.1200/JCO.2017.35.15_suppl.7024
Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130(21):2295–2306
pubmed: 28924019
pmcid: 5701525
doi: 10.1182/blood-2017-06-793141
Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5(177):177ra38
Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH et al (2016) Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 34(10):1112–1121
pubmed: 26811520
pmcid: 4872017
doi: 10.1200/JCO.2015.64.5929
Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S et al (2013) Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122(17):2965–2973
pubmed: 24030379
pmcid: 3811171
doi: 10.1182/blood-2013-06-506741
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al (2014) Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra25
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509–1518
pubmed: 23527958
pmcid: 4058440
doi: 10.1056/NEJMoa1215134
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517–528
Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449–459
pubmed: 29385376
pmcid: 6637939
doi: 10.1056/NEJMoa1709919
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439–448
pubmed: 29385370
pmcid: 5996391
doi: 10.1056/NEJMoa1709866
Dong L, Chang LJ, Zhiyong G, Lu DP, Zhang JP, Wang JB et al (2015) Chimeric antigen receptor 4SCAR19-modified T cells in acute lymphoid leukemia: a phase II multi-center clinical trial in China. Blood 126(23):3774
doi: 10.1182/blood.V126.23.3774.3774
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507–1517
pubmed: 25317870
pmcid: 4267531
doi: 10.1056/NEJMoa1407222
Rheingold SR, Chen LL, Maude SL, Aplenc R, Barker C, Barrett DM et al (2015) Efficient trafficking of chimeric antigen receptor (CAR)-modified T cells to CSF and induction of durable CNS remissions in children with CNS/combined relapsed/refractory ALL. Blood 126(23):3769
doi: 10.1182/blood.V126.23.3769.3769
Jacoby E, Bielorai B, Avigdor A, Itzhaki O, Hutt D, Nussboim V et al (2018) Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Am J Hematol 93(12):1485–1492
pubmed: 30187944
doi: 10.1002/ajh.25274
pmcid: 30187944
Zhang H, Hu Y, Wei G, Wu W, Huang H (2019) Successful chimeric antigen receptor T cells therapy in extramedullary relapses of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant
Wang D, Shi R, Wang Q, Li J (2018) Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report. Onco Targets Ther 11:6327–6332
pubmed: 30319272
pmcid: 6167997
doi: 10.2147/OTT.S164430
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625–638
pubmed: 30592986
doi: 10.1016/j.bbmt.2018.12.758
pmcid: 30592986
Chang LJ, Dong L, Liu YC, Tsao ST, Li YC, Liu L et al (2016) Safety and efficacy evaluation of 4SCAR19 chimeric antigen receptor-modified T cells targeting B cell acute lymphoblastic leukemia—three-year follow-up of a multicenter phase I/II study. Blood 128(22):587
Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH et al (2017) High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia 31(12):2587–2593
pubmed: 28490811
doi: 10.1038/leu.2017.145
pmcid: 28490811
National Cancer Institute. Common terminology criteria for adverse events v4.3 (CTCAE)
National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 5.0
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188–195
pubmed: 24876563
pmcid: 4093680
doi: 10.1182/blood-2014-05-552729
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL et al (2018) Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47–62
pubmed: 28925994
doi: 10.1038/nrclinonc.2017.148
pmcid: 28925994
Porter D, Frey N, Wood PA, Weng Y, Grupp SA (2018) Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol 11(1):35
pubmed: 29499750
pmcid: 5833070
doi: 10.1186/s13045-018-0571-y
Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O et al (2018) The biological basis and clinical symptoms of CAR-T therapy-associated toxicites. Cell Death Dis 9(9):897
pubmed: 30181581
pmcid: 6123453
doi: 10.1038/s41419-018-0918-x
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664–679
pubmed: 27076371
pmcid: 5448406
doi: 10.1158/2159-8290.CD-16-0040
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7(303):303ra139
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73
Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL et al (2016) Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J Immunol Methods 434:1–8
pubmed: 27049586
pmcid: 5490247
doi: 10.1016/j.jim.2016.03.005
Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C et al (2016) Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol 9(1):70
pubmed: 27526682
pmcid: 4986179
doi: 10.1186/s13045-016-0299-5
Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB et al (2017) Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med 377(8):783–784
pubmed: 28834486
doi: 10.1056/NEJMc1704610
pmcid: 28834486
van der Heyde HC, Nolan J, Combes V, Gramaglia I, Grau GE (2006) A unified hypothesis for the genesis of cerebral malaria: sequestration, inflammation and hemostasis leading to microcirculatory dysfunction. Trends Parasitol 22(11):503–508
pubmed: 16979941
doi: 10.1016/j.pt.2006.09.002
pmcid: 16979941
Grau GE, Heremans H, Piguet PF, Pointaire P, Lambert PH, Billiau A et al (1989) Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proc Natl Acad Sci U S A 86(14):5572–5574
pubmed: 2501793
pmcid: 297664
doi: 10.1073/pnas.86.14.5572
Danylesko I, Chowers G, Shouval R, Besser MJ, Jacoby E, Shimoni A et al (2019) Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. Curr Res Transl Med
Jacoby E (2019) The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia. Bone Marrow Transplant 54(Suppl 2):810–814
Kenderian SS, Porter DL, Gill S (2017) Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse. Biol Blood Marrow Transplant 23(2):235–246
pubmed: 27638367
doi: 10.1016/j.bbmt.2016.09.002
pmcid: 27638367
Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C et al (2015) Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Blood 126(23):681
Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G et al (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109(3):944–950
pubmed: 17032921
doi: 10.1182/blood-2006-05-018192
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75(3):555–562
pubmed: 2297567
doi: 10.1182/blood.V75.3.555.555
pmcid: 2297567
Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL et al (2014) The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 children’s oncology group/pediatric blood and marrow transplant consortium trial. Blood 123(13):2017–2025
pubmed: 24497539
pmcid: 3968388
doi: 10.1182/blood-2013-10-534297
Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A et al (2009) Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group. J Clin Oncol 27(3):377–384
pubmed: 19064980
doi: 10.1200/JCO.2008.17.6065
pmcid: 19064980
Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K et al (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129(25):3322–3331
pubmed: 28408462
pmcid: 5482103
doi: 10.1182/blood-2017-02-769208
Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M et al (2015) 4–1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581–590
pubmed: 25939063
pmcid: 4458184
doi: 10.1038/nm.3838
Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D et al (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17(8):1453–1464
pubmed: 19384291
pmcid: 2805264
doi: 10.1038/mt.2009.83
Mejstrikova E, Hrusak O, Borowitz MJ, Whitlock JA, Brethon B, Trippett TM et al (2017) CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J 7(12):659
pubmed: 29259173
pmcid: 5802535
doi: 10.1038/s41408-017-0023-x
Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G et al (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5(12):1282–1295
pubmed: 26516065
pmcid: 4670800
doi: 10.1158/2159-8290.CD-15-1020
Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA et al (2017) CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother 40(5):187–195
pubmed: 28441264
pmcid: 5424577
doi: 10.1097/CJI.0000000000000169
Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H et al (2016) CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun 7:12320
pubmed: 27460500
pmcid: 4974466
doi: 10.1038/ncomms12320
Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O et al (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127(20):2406–2410
pubmed: 4874221
pmcid: 4874221
doi: 10.1182/blood-2015-08-665547
Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA et al (2008) Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322(5906):1377–1380
pubmed: 19039135
pmcid: 2746051
doi: 10.1126/science.1164266
Rayes A, McMasters RL, O’Brien MM (2016) Lineage Switch in MLL-Rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer 63(6):1113–1115
pubmed: 26914337
doi: 10.1002/pbc.25953
pmcid: 26914337
Nagel I, Bartels M, Duell J, Oberg HH, Ussat S, Bruckmueller H et al (2017) Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood 130(18):2027–2031
pubmed: 28827408
pmcid: 5726343
doi: 10.1182/blood-2017-05-782888
Oberley MJ, Gaynon PS, Bhojwani D, Pulsipher MA, Gardner RA, Hiemenz MC et al (2018) Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia. Pediatr Blood Cancer 65(9):e27265
Lee DW, Stetler-Stevenson M, Yuan C, Shah NN, Delbrook C, Yates B et al (2016) Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-car hematopoietic stem cell transplantation. Blood 128(22):218
Zhang Y, Chen H, Song Y, Tan X, Zhao Y, Liu X et al (2019) Post-chimeric antigen receptor T-cell therapy haematopoietic stem cell transplantation for 52 cases with refractory/relapsed B-cell acute lymphoblastic leukaemia. Br J Haematol